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Pluripotent or multipotent stem cells are involved in development and tissue homeostasis; they have the ability to self-renew 
and differentiate into various types of functional cells. To maintain these properties, stem cells must undergo sustained or un-
limited proliferation that requires the stabilization of telomeres, which are essential for chromosome end protection. Telomer-
ase, an RNA-dependent DNA polymerase, synthesizes telomeric DNA. Through the lengthening of telomeres the lifespans of 
cells are extended, or indefinite proliferation is conferred; this is intimately associated with stem cell phenotype. This review 
highlights our current understanding of telomerase as a “stemness” enzyme and discusses the underlying implications. 
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Eukaryotic chromosomes terminate with tandem arrays of 
repetitive DNA sequences known as telomeres. This telo-
meric DNA, together with its binding proteins, forms a pro-
tective cap at the ends of chromosomes for maintaining ge-
nomic integrity and stability [1,2]. In human somatic cells, 
telomere sequences are 815 kb long TTAGGG repeats that 
shorten progressively with each round of cell division ow-
ing to the end replication problem; this shortening of telo-
meres commences during fetal development [1,35]. When 
telomeres become too short (dysfunctional) to protect 
chromosomes, the DNA damage response is activated, trig-
gering permanent growth arrest of cells (replicative senes-
cence) or apoptosis. Progressive telomere erosion is be-
lieved to function as a mitotic clock for controlling cellular 
lifespan and preventing abnormal cell proliferation [2,5]. 
Certain types of normal human cells exhibit strong replica-
tion potential, while malignant cells are capable of prolifer-
ating indefinitely. In all these cases, telomere shortening 
coupled with cell replication must be compensated for to 
circumvent senescence and apoptosis. Telomerase, an 
RNA-dependent DNA polymerase, synthesizes or extends 
telomeric DNA, and is widespread in those cells. It has been 
established that activation of telomerase is the most com-
mon strategy to stabilize telomere length in both normal and 
malignant cells, thereby maintaining sustained and unlim-
ited proliferation capacity [57]. 
Stem cells are defined as cells with two important prop-
erties: they have the capacity for self-renewal; and they are 
able to differentiate into any somatic cell type [8,9]. In 
mammals, it is generally considered that there are embry-
onic, germinal and adult stem cells. All these stem cell types 
possess a remarkable ability to undergo asymmetric mitotic 
divisions that produce two daughter cells. Alternatively, 
they can undergo symmetric division in a stochastic manner 
to produce more stem cells and/or differentiating cells. One 
daughter cell possesses the properties of a stem cell, while 
the other differentiates to replenish specialized cell types. 
Embryonic stem cells (ESCs) are present in the inner cell 
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mass of blastocysts and give rise to all derivatives of the 
three primary germ layers: ectoderm, endoderm and meso-
derm. Germinal stem cells of the embryo undergo differen-
tiation to generate either eggs or sperm, whereas adult stem 
cells (ASCs) divide and differentiate to replace damaged 
cells in tissues, providing the body with an internal repair 
system. In recent years, reprogramming technology has 
been used to successfully convert differentiated cells into 
pluripotent stem cells, which have been coined induced plu-
ripotent stem cells (iPSCs) [1012]. These iPSCs are very 
much similar to ESCs [12]. In addition to the stem cells 
described above, many malignancies contain a fraction of 
cells that have functional similarities to stem cells. These 
cells are usually responsible for tumor initiation, develop-
ment, metastasis and recurrence; the so-called cancer stem 
cells (CSCs) [13,14].  
Regardless of stem cell origin, sustained or indefinite 
proliferation potential is a key characteristic of all stem cells 
required for self-renewal. To achieve this, stem cells must 
be able to stabilize their telomere length. Accumulating 
evidence indicates that telomerase activation is widespread 
in stem cells, with telomerase levels rate-limiting for the 
self-renewal potential of stem cells. Therefore, telomerase is 
believed to act as a “stemness” enzyme. The present review 
summarizes our current understanding of telomerase as a 
stemness enzyme, and discusses its potential biological and 
clinical implications. 
1  Telomerase activity and subunit expression in 
normal and cancer cells 
Telomerase is a large ribonucleoprotein complex containing 
many known and uncharacterized elements. The core en-
zyme comprises telomerase reverse transcriptase (TERT), 
an RNA component (TERC) and dyskerin (Figure 1) [15]. 
TERT is a catalytic subunit, while TERC serves as the tem-
plate for the addition of TTAGGG telomere repeats [6,7]. 
Human TERC RNA is ubiquitously expressed in various 
normal tissues and cells. Dyskerin, encoded by DKC1, is 
widespread in normal cells and is required for hTERC sta-
bility and recruitment [16,17]. In contrast, TERT expression 
is repressed in most differentiated cells during the later 
stages of fetal development and after birth [3,6,7]. General-
ly, TERT expression is associated with acquisition of te-
lomerase activity; the introduction of TERT into telomer-
ase-deficient cells is sufficient to activate telomerase [6,18]. 
Therefore, it is widely considered that TERT is a crucial 
rate-limiting component for controlling telomerase activity. 
Telomerase activity is detectable in up to 90% of human 
malignancies. This is in sharp contrast to that seen in nor-
mal differentiated cells, and suggests broad re-activation of 
telomerase during oncogenesis [6,7]. Alterations in the lev-
els of various telomerase components could contribute to its 
activation to a certain extent, however, the induction of 
TERT expression is the determining step for acquisition of 
telomerase activity during cellular transformation [6]. A 
close association between presence of telomerase activity 
and TERT expression is seen in both primary cancers and 
cancer-derived cell lines. Given these observations, numer-
ous efforts have been made to elucidate how the TERT gene 
is activated during oncogenesis. Results from studies in-
volving cancer cells have significantly contributed to the 
understanding of telomerase/TERT regulation in normal 
cells as both normal and malignant cells share considerable 
similarities with respect to regulating telomerase activity 
and TERT expression [19].    
2  Telomerase in normal stem cells 
Human stem cells are one of the few normal cell types that 
exhibit TERT and telomerase activity [20]; however, there 
is a significant difference in telomerase biology between 
ESCs and ASCs (Figure 1). In vitro cultured ESCs exhibit 
an immortal phenotype with the ability to proliferate indefi-
nitely [21]. Consistently high levels of telomerase activity, 
coupled with stabilized or long telomeres, are seen in these 
cells. When human ESCs undergo differentiation, their te-
lomerase activity and TERT expression is down-regulated. 
As a result of this down-regulation, telomere shortening can 
no longer be compensated for. It has been suggested that 
such high telomerase activity is an essential element for 
maintenance of the immortal and pluripotent phenotypes of 
human ESCs. Inhibiting TERT expression and telomerase 
activity led to reduced ESC proliferation, with an increased 
number of cells in the G1 phase and a reduced number in 
the S phase [22]. Suppression of TERT leads to loss of plu-
ripotency and differentiation of human ESCs towards ex-
traembryonic and embryonic lineages [22,23]. In contrast, 
ectopic TERT expression and increased telomerase activity 
stimulate the proliferation and colony-forming ability of 
human ESCs, and increase the number of cells in the S 
phase of the cell cycle [22].  
The regulatory mechanism underlying TERT expression 
and telomerase activity in ESCs has recently been investi-
gated. Krüppel-Like Transcription Factor 4 (KLF4), a core 
component of the pluripotency transcriptional network, 
plays a key role in regulating TERT transcription in human 
ESCs [24]. KLF4 binds to its motif on the TERT core pro-
moter and activates TERT transcription. When KLF4 was 
inhibited using RNA interference (RNAi), TERT expression 
and telomerase activity were significantly reduced in human 
ESCs. Furthermore, β-catenin, another pluripotency-related 
transcription factor, stimulates TERT transcription by inter-
acting with KLF4 [25,26]. β-catenin-deficient murine ESCs 
expressed lower levels of TERT and telomerase activity. 
Using RNAi to screen regulators for telomerase in murine 
ESCs, Counssens et al. identified hypoxia inducible fac-
tor-1α (HIF-1α) as a potent trans-activator of the TERT gene 
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Figure 1  Telomerase in human stem cells. The telomerase complex comprises TERT (telomerase reverse transcriptase), TERC (telomerase RNA template), 
Dsykerin, NOP10, Reptin, Pontin and other factors that are yet to be identified. Telomere lengthening is the canonical function of telomerase. Embryonic 
stem cells (ESCs) express high levels of telomerase activity that are required to maintain telomere length. Adult stem cells (ASC) also express telomerase, 
but the levels of expression are lower than those in ESCs. ASCs exhibit gradual telomere shortening with increasing age and become senescent (telomere 
dysfunction). Induced pluripotent stem cells (iPSCs) acquire telomerase, and their telomeres are restored to lengths similar to those in ESCs. In general, 
cancer stem cells (CSCs) have shorter telomeres than those in normal cells, however high levels of telomerase activity stabilize their telomeres. Telomerase 
has multiple activities, independent of its telomere lengthening action. These functions might also significantly affect the phenotype and other characteristics 
of ESCs, ASCs, iPSCs and CSCs. 
[27]. Taken together, various stemness factors and signaling 
pathways cooperate to maintain high levels of TERT ex-
pression and telomerase activity in ESCs.   
Unlike human ESCs, ASCs are not immortal, and exhibit 
signs such as decreased self-renewal, reduced clonal stabil-
ity, reduced homing and engraftment, and biased lineage 
commitment [2,8,9,28]. Telomerase activity and TERT ex-
pression, coupled with relatively longer telomeres, are 
widely observed in stem cell compartments in many tissues 
and organs [20,29]. Among human ASCs, hematopoietic 
stem cells (HSCs) are the most widely studied. It has been 
noticed that HSCs undergo telomere erosion with increasing 
age, but at a slower rate compared with differentiated 
progenies or lymphocytes; this would suggest inadequate 
telomere maintenance [30,31]. Telomerase activity is de-
tectable in HSCs, but at levels lower than those observed in 
human ESCs. Despite this reduction, moderate levels of 
telomerase activity are required for HSCs to support rapid 
turnover of differentiated blood cells [32]. 
The critical role of telomerase in ASCs, especially in 
human and mouse HSCs, has been shown through studies 
on individuals with telomerase gene alterations and using 
telomerase knockout mice. Dyskeratosis congenital (DC) is 
a genetic disease, with bone marrow failure occurring in 
80% of DC patients [33]. Mutations in DKC1, which en-
codes dyskerin, are etiological for X-linked DC. Autosomal  
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forms (recessive or dominant) of DC are due to mutations in 
TERT, TERC or other telomerase components. These muta-
tions result in defective telomerase activity, leading to ac-
celerated telomere shortening [16,17,33–35]. Another con-
sequence of this is the severe impairment of HSC self-  
renewal and proliferation, which eventually results in bone 
marrow failure. The stem cells of DC patients in other or-
gans and tissues are affected by shortened telomeres, clini-
cally manifesting as nail dystrophy, oral leukoplakia, ab-
normal skin pigmentation and increased cancer risks [17]. 
Additionally, TERT and TERC mutations have been ob-
served in other human diseases, including aplastic anemia 
and myelodysplastic syndrome, where HSCs are damaged 
by accelerated telomere erosion because of insufficient te-
lomerase activity [3537]. Many of these telomerase dis-
ease-related manifestations are observed in telomerase 
knockout mice [3840]. In addition to the direct effects of 
telomerase deficiency on ASCs, mouse experiments have 
also shown that environmental alterations mediated by te-
lomere dysfunction due to lack of telomerase significantly 
impair HSC function and engraftment [41].  
Recent studies have revealed multiple biological activi-
ties of telomerase or TERT, in addition to its telomere 
lengthening function (Figure 1) [42]. In vitro murine ESCs 
that overexpressed TERT were much more resistant to 
apoptosis and oxidative stress [43]. In vivo studies showed 
that TERT was a critical determinant for the mobilization 
and proliferation of quiescent epidermal stem cells. TERT 
overexpression promoted stem cell mobilization and hair 
growth, while an absence of TERT resulted in inhibited 
mobilization and proliferation of stem cells out of their 
niche, and impaired hair growth [44,45]. Mechanistically, 
TERT functions as a transcriptional modulator of the 
Wnt/β-catenin signaling pathway [46]. TERT directly regu-
lates Wnt/β-catenin signaling by serving as a cofactor in a 
β-catenin transcriptional complex. In cultured cells and in 
vivo, TERT activates Wnt-dependent reporters by interact-
ing with BRG1, a SWI/SNF-related chromatin remodeling 
protein [46]. More recently, a global decline in genomic 
CpG methylation levels coupled with the down-regulation 
of DNA methyltransferase 3b expression was observed in 
ESCs derived from TERT knockout mice, triggering unsta-
ble differentiation of ESCs. Those findings revealed an un-
expected role for TERT and/or telomere stability in the ge-
nome-wide epigenetic regulation of cell differentiation [39]. 
Additionally, TERT knockout-mediated telomere dysfunc-
tion was shown to be associated with impaired mitochon-
drial biogenesis and function, decreased gluconeogenesis, 
cardiomyopathy, and increased levels of reactive oxygen 
species in mice [47]. It is likely that these TERT-related 
mitochondrial defects can affect the fates of stem cells [48]. 
Based on the above findings, the independent telomere 
lengthening function of telomerase is important for the 
phenotype of stem cells.  
3  Telomerase in iPSCs 
Reprogramming differentiated somatic cells into pluripotent 
stem cells has emerged as a way of producing pa-
tient-specific stem cells as these cells could be a possible 
source for autologous pluripotent cell transplantation [49]. 
Initially, a single cell via somatic cell nuclear transfer tech-
nology was used for reprogramming somatic cells, and the 
cloning of animals such as Dolly the sheep [49,50]. Yama-
naka et al. [10,11] successfully reprogrammed differentiated 
fibroblasts into iPSCs using four key transcription factors 
(Oct4, Sox2, c-Myc, and Klf4), which ushered in a new era 
in stem cell and regenerative medicine research. To date, 
iPSCs have been generated using different types of cells of 
various origin with different combinations of reprograming 
factors [12].  
Terminally differentiated normal human cells have a lim-
ited lifespan due to telomere shortening. Telomere erosion 
must be prevented during reprogramming for iPSCs to ac-
quire sustained proliferation potential. Yamanaka et al. 
[10,11] found that telomerase was activated in iPSCs; this 
was confirmed in later studies by other researchers [5153]. 
Mathew et al. [54] analyzed the regulation of TERT and 
telomerase activation in reprogramed human fibroblasts; 
TERT was transcriptionally activated in reprogramed cells, 
however, levels of TERT expression and telomerase activity 
differed depending on the extent of reprograming [54]. Ful-
ly reprogramed human fibroblasts exhibited the highest lev-
els of TERT expression and telomerase activity [54]. How-
ever, TERT transcription and telomerase was also activated 
in incompletely reprogramed fibroblasts, but their telomere 
length was not restored. Only iPSC clones with the highest 
TERT expression/telomerase activities that expressed all 
pluripotency markers exhibited robust replication potential 
and formed teratomas [54]. These findings strongly suggest 
that TERT/telomerase expression levels and telomere length 
are important parameters for determining whether an iPSC 
line is fully reprogramed. 
The essential role of telomerase in iPSCs is further 
demonstrated in studies of telomerase-defective or deficient 
murine cells [52]. Somatic cells derived from third genera-
tion TERC-knockout/telomerase null mice failed to generate 
iPSCs, while the reintroduction of telomerase enabled the 
cells to be efficiently reprogrammed [29]. This indicates the 
importance of telomerase in iPSC generation and function-
ality. When reprogramming fibroblasts derived from indi-
viduals with loss-of-function mutations in the TERT or 
TERC genes, Winkler et al. [55] observed lower rates for 
telomere elongation and defective hematopoiesis in mutant 
telomerase-derived iPSCs. In another study, reduced te-
lomerase activity and progressive telomere erosion was as-
sociated with loss of self-renewal potential and early senes-
cence of iPSCs derived from patients with mutated TERT, 
TERC or dyskerin genes [56]. In contrast, Agarwal et al.  
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[53] derived iPSCs from two patients with mutations in 
DKC1, and from one patient with a heterozygous null muta-
tion in TERC. They observed telomere elongation in iPSCs, 
and TERT and TERC upregulation comparable with those in 
wild-type iPSCs. The implications of these seemingly con-
tradictory results remain to be resolved. Clonal variation, 
secondary genetic alterations, and differing culture condi-
tions might contribute to the discrepancies observed, how-
ever, further studies are required to elucidate these issues. 
It is evident from the above data that telomerase is highly 
activated during somatic cell reprogramming, and that te-
lomerase-mediated telomere homeostasis is essential during 
iPSC generation, self-renewal and differentiation.   
4  Telomerase in CSCs 
Many human malignancies are hierarchical with a unique 
self-renewing population of cells at the top of the hierarchy; 
this has given rise to the CSC hypothesis [14]. CSCs have 
the ability to initiate tumor formation, to self-renew in serial 
transplantation assays, and to differentiate into non-tumor- 
igenic progenies. Although CSCs share functional similari-
ties to normal stem cells, they are not necessarily derived 
from normal stem cells. CSCs are known to actively prolif-
erate, which is in contrast to normal stem cells that general-
ly cycle at a slow rate [57]. To maintain these characteris-
tics and functionality, the telomere length of CSCs must be 
stabilized by some mechanisms. Results from a number of 
studies have shown the presence of telomerase activity 
and/or TERT expression in CSCs from different malignan-
cies [20]. Castelo-Branco et al. [58] compared telomerase 
expression between CSCs and non-CSC cells derived from 
patients with glioblastoma and neuroblastoma. They found 
that telomerase was activated in CSCs but not in non-CSC 
cells [58]. When telomerase activity was inhibited, and 
thereby telomere maintenance was disrupted, in those neural 
CSCs, their self-renewal capacities were significantly im-
paired or even lost. Those findings clearly indicate a critical 
role for telomerase and/or stabilized telomere length in 
CSCs. However, analysis of glioma-derived telomer-
ase-proficient GOS-3 cells in a different study revealed a 
CD133+ CSC subpopulation that expressed TERT mRNA at 
levels 100-fold lower than those in the CD133 fraction. 
Serum starvation of GOS-3 cells led to increased expression 
of the stemness marker CD133 and down-regulation of 
TERT expression [59]. Because the authors did not evaluate 
other CSC properties in GOS-3 cells, it is unclear whether 
those CD133+ GOS-3 cells were true CSCs. Studies on 
breast, prostate, and pancreatic cancers demonstrated that 
telomerase was highly activated in CSCs and indispensable 
for the maintenance of the CSC phenotype and characteris-
tics [20,60,61].   
Telomerase is activated and responsible for telomere 
elongation in the vast majority of malignancies. However, 
an alternative telomere lengthening (ALT) mechanism op-
erates during telomere stabilization in 10%–15% of te-
lomerase-deficient cancers [62,63]. ALT is an unconserved, 
telomerase-independent telomere lengthening pathway in-
volving the transfer of telomere tandem repeats between 
sister chromatids; it is frequently activated in malignancies 
of mesenchymal origin [63]. Approximately 33% of glio-
mas acquire ALT activity, and Silvestre et al. [64] charac-
terized CSCs derived from patients with glioblastoma lack-
ing telomerase activity. They found that those CSCs exhib-
ited a typical ALT telomere length profile that was long and 
heterogeneous; this was observed in all other ALT+ tumor 
cells. ALT+ CSCs expressed neural stem cell markers and 
formed intracranial tumors in immunocompromised mice. 
The ALT pathway can maintain the phenotype and function 
of CSCs as efficiently as telomerase. It has been noted that 
ALT+ CSCs appear to be more resistant to radiotherapy than 
telomerase+ CSCs in glioblastoma patients [64].   
Multiple biological activities of telomerase/TERT, be-
yond its telomere lengthening function, have been demon-
strated [42]. It was shown that the effect of TERT on CSCs 
could be independent of its catalytic activity. In gastric 
cancer cells, both wild-type TERT and its dominant nega-
tive variant were observed to induce the expression of 
CD44, a CSC marker, to enhance the formation of spheroid 
colonies, to enhance self-renewal capacities, and to enhance 
in vivo metastasis [65]. Additionally, cancer cells possess 
strong phenotypic plasticity, and dynamic phenotypic 
switching can occur between CSCs and non-CSC cells in 
response to changing intrinsic and microenvironmental 
conditions. A number of reports have shown that cancer 
cells, when undergoing epithelial-mesenchymal transition 
(EMT), frequently acquire CSC properties [13,66]. Similar-
ly, TERT could stimulate the stemness of cancer cells via 
EMT [65]. These findings suggest that TERT increases the 
phenotypic plasticity of cancer cells and promotes the con-
version of cells from the non-CSC to the CSC form, thereby 
amplifying the CSC pool.  
Collectively, telomerase/TERT contributes to the CSC 
phenotype via telomere maintenance and independent telo-
mere lengthening mechanisms. In addition, the ALT path-
way is capable of maintaining CSC phenotypes and activi-
ties in telomerase-deficient malignancies. All these findings 
provide important rationales for designing telomerase-based 
strategies that can target CSCs. 
5  Conclusion and perspectives 
We have discussed recent studies involving telomerase reg-
ulation and its role in various stem cells. Current findings 
suggest that telomerase plays critical roles, in stem cell bi-
ology and function. Telomerase would appear to be a stem-
ness enzyme and is rate-limiting for the proliferation, 
self-renewal and differentiation of stem cells including 
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ESCs, ASCs, iPSCs and CSCs (Figure 1). In both normal 
and malignant stem cells, telomerase plays its parts by 
elongating telomeres and via an independent telomere 
lengthening function. Aberrant or impaired telomerase ac-
tivity leads to defective stem cell function, thereby causing 
diseases. However, we have only touched the tip of the ice-
berg thus far and many outstanding questions remain to be 
defined. Nevertheless, the collected data will be very useful 
for designing telomerase-based strategies in regenerative 
medicine, the intervention of aging, and cancer therapy. 
Hopefully, we will be able to specifically manipulate the 
stemness enzyme in stem cells in time, place and quality for 
therapeutic purposes in the near future.  
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